BSX

#218
Boston Scientific Corporation Common Stock
48.3 3 USD
-2.21%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
48.13
48.63
Rango anual
48.13
109.49
Cambio diario
-2.21%
Variación mensual
-15.33%
Variación en los últimos 6 meses
-52.52%
Cambio anual
-53.76%
Cierres anteriores
49.4 2
Open
48.3 0
Mínimo
48.1 3
High
48.6 3
Volumen
11.2 K
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 71.84 B
  • Employee 59 K
  • Founded 1979
  • CEO Michael F. Mahoney
  • Website www.bostonscientific.com
  • Headquarter Delaware, United States
  • FIGI BBG000C0LW92
  • Industry Aparatos médicos
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
26.26
Relación precio/flujo de caja
4.55

Boston Scientific Corporation Common Stock

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

Noticias